Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Tracking of autologous adipose-derived mesenchymal stromal/stem cells after intravenous administration: a pilot study in a dog with induced acute bladder injury.

Porato M., Antoine N., Waroux O., Piret J., Noël S., Hamaide A.

Laboratory Study on Scar, published in Front Vet Sci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Front Vet Sci (2025)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
41427138
PMCID
PMC12716081
DOI
10.3389/fvets.2025.1644746

Abstract (original English)

Introduction Regenerative therapy for bladder diseases has been studied in rodent to restore bladder function after a chronic and irreversible bladder wall deterioration. These studies rarely demonstrate the presence of stem cells in the bladder. Cell-tracking after intravenous (IV) administration of stem cells enables to confirm the homing potential of an injury. Our objective was to assess, in one dog, the homing capability of autologous adipose-derived mesenchymal stromal/stem cells (ADMSCs) injected intravenously to an acute bladder injury. Methods Adipose-derived mesenchymal stromal/stem cells were isolated from the subcutaneous tissue of a dog and labelled. As a homing signal, a full-thickness bladder biopsy representing an acute injury was created in this dog (day 0, control time). Twenty million autologous PKH26-labelled ADMSCs were injected in the cephalic vein on days 1, 4 and 8. Urinalysis was performed (day 5). Bladder biopsy was repeated at the location of the previous scar to assess the presence of labelled ADMSCs in the bladder wall (day 10). Results Labelled ADMSCs were observed in the second bladder biopsy, not in the initial biopsy nor in urine. The only adverse event mild, self-limiting hematuria. Complete cell blood count, blood urea nitrogen and plasma creatinine were within normal limits (day 5). Conclusion The comparison of bladder biopsies before and aft

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research